Phaseline

Targets › IL18

IL18 (Interleukin-18): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Oct 2027.

Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses. Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators. (UniProt, Q14116)

Open in Phaseline: the race on IL18, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Apollo TherapeuticsCamoteskimab
Interleukin-18 cross-linking agent
IL18Phase 2Atopic DermatitisOct 2027
Memorial Sloan Kettering Cancer Center19-28z/IL-18 CAR T cells
CAR-T cell therapy targeting CD19 with IL-18 co-expression
CD19, IL18Phase 1Philadelphia-Negative ALLFeb 2028
GSKAletekitug (GSK1070806)
Anti-IL-18 monoclonal antibody
IL18Phase 1Colitis, UlcerativeMar 2028
Simcha IL-18ST-067
Engineered variant of human interleukin-18
IL18Phase 1Cancer–

Conditions

Colitis, Ulcerative (2) Cancer (1) Atopic Dermatitis (1) Philadelphia-Negative ALL (1)

Modalities

antibody (2), mixed (1), other (1)

Companies

Simcha IL-18 (1) Apollo Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) GSK (1)

Related targets

CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.